Breaking News: Hepion Pharmaceuticals’ Phase 2 ALTITUDE NASH Trial Successfully Meets Primary and Secondary Endpoints, Significantly Improving Liver Function and Multiple NASH Biomarkers
Breaking News: Hepion Pharmaceuticals’ Phase 2 ALTITUDE NASH Trial Successfully Meets Primary and Secondary Endpoints, Significantly Improving Liver Function and Multiple NASH Biomarkers Improvements in Liver Function and NASH Biomarkers In a groundbreaking development, Hepion Pharmaceuticals has announced that their Phase 2 ALTITUDE NASH trial has achieved both primary and secondary endpoints. This milestone marks…